Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214993 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01214993 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 38 participants.
The verdict
NCT01214993, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The current study is designed to confirm the mechanism behind the increase in serum creatinine observed during GSK1349572 therapy; specifically, the study will determine whether GSK1349572 has any effect on glomerular filtration rate (GFR) or effective renal plasma flow. Absent such effects, one may conclude that the small increases in serum creatinine observed are due to the inhibition of the tubular secretion of creatinine via organic cation transporter 2 (OCT2) consistent with in vitro data. .
Interventions
- DRUG Placebo
- DRUG GSK1349572
- DRUG Iohexol Injection
- DRUG Para-aminohippurate infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214993
The ClinicalTrials.gov registry entry for NCT01214993 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01214993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214993 about?
NCT01214993 is a clinical study titled "A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects". The current study is designed to confirm the mechanism behind the increase in serum creatinine observed during GSK1349572 therapy; specifically, the study will determine whether GSK1349572 has any effect on glomerular filtration rate (GFR) or effective renal plasma flow. Absent such effects, one may...
What is the current status of trial NCT01214993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2010-10. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01214993?
The interventions under investigation include: Placebo (DRUG), GSK1349572 (DRUG), Iohexol Injection (DRUG), Para-aminohippurate infusion (DRUG).
Who is sponsoring clinical trial NCT01214993?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.